Clinical trials: Sodium Glucose Co-Transporter 2 Inhibitors
Left Cardiac Catheterization, Percutaneous Coronary Intervention
Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention
Left heart catheterization and percutaneous coronary intervention (PCI) has become a useful tool in interventional cardiology, in which iodinated contrast media is used.
- Conditions
- Left Cardiac Catheterization, Percutaneous Coronary Intervention, Acute Kidney Injury, Sodium-glucose Co-transporter 2 Inhibitors
- Trial name
- NCT04806633
- Testing
- Dapagliflozin 5mg
- Where
- 2 sites in Greece
- Volunteers
- 1,722 people
- Sponsor
- G.Gennimatas General Hospital
Type2diabetes
Effect of SGLT-2 Inhibitors in Patients With T2DM and Moderate to Severe Liver Fibrosis
This retrospective study will be of 12 months duration where 40 T2DM patients coming to FORTIS C-DOC hospital in OPD with F3 fibrosis will be included in the study.
- Trial name
- NCT05943899
- Where
- India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Kidney Transplant Recipient, Sodium Glucose Co-Transporter 2 Inhibitors
SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial
The goal of this clinical trial is to find out whether 12 months of treatment with the SGLT2 inhibitor Forxiga® (dapagliflozin 10 mg once daily), compared with placebo, can reduce the risk of developing post-transplant diabetes…
- Conditions
- Kidney Transplant Recipient, Sodium Glucose Co-Transporter 2 Inhibitors, Non-Diabetic Patients, Randomized Controlled Trial (RCT)
- Trial name
- SGL-TX-PTDM (NCT07682350)
- Testing
- SGLT2i
- Where
- 3 sites in Denmark
- Volunteers
- 184 people
- Sponsor
- Odense University Hospital
Diabetes Mellitus, Type 2, Cognitive Functions Confusion
Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
Type 2 diabetes is associated with diabetic cognopathy, the prevalence of Alzheimer's Disease(AD) in T2DM patients is 1.5 to 2.5 times higher than the general population.
- Trial name
- ESCDP (NCT04304261)
- Testing
- Canagliflozin, Sitagliptin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Third Military Medical University
Chronic Kidney Diseases
Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria
The aim of this study is to test the hypothesis that the effects on albuminuria of combination treatment with the endothelin receptor antagonist zibotentan and SGLT2i dapagliflozin are complimentary and additive while the fluid…
- Trial name
- ZODIAC (NCT05570305)
- Testing
- Zibotentan, Dapagliflozin, Dapagliflozin and Zibotentan
- Where
- 7 sites in United States, Canada and 3 more
- Volunteers
- 42 people
- Sponsor
- University Medical Center Groningen
Heart Failure With Reduced Ejection Fraction, End Stage Renal Disease on Dialysis
Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease
In patients with ESRD, up to 20% of patients suffer from HFrEF, leading to significant CV morbidity and mortality. Several drug classes that provide survival benefits for patients with HFrEF, including SGLT2i, lack data regarding…
- Trial name
- EMPA-RRED (NCT06249932)
- Testing
- Empagliflozin 25 MG
- Where
- 2 sites in Taiwan
- Volunteers
- 95 people
- Sponsor
- National Taiwan University Hospital
Type 2 Diabetes, Ketonemia
Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy
The use of sodium glucose co-transporter 2 inhibitors (SGLT2i) has been associated with increased serum ketone levels. However, most previous studies included subjects who were either insulin or even drug naïve with relatively…
- Trial name
- NCT03959501
- Testing
- Dapagliflozin 10 mg, Sitagliptin 100mg
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- The University of Hong Kong
Prediabetic State, Impaired Fasting Glucose
Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients
Pre-diabetes is a state characterized by subclinical impairment in glycemic variables that is intermediate between normal glucose tolerance (NGT) and diabetes.
- Conditions
- Prediabetic State, Impaired Fasting Glucose, Impaired Glucose Tolerance
- Trial name
- NCT05914857
- Testing
- Dapagliflozin 10mg Tab, lifestyle interventions
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Yangjin
Heart Failure With Reduced Ejection Fraction
HF Patients With LVADs Being Treated With SGLT2i
The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).
- Trial name
- NCT05278962
- Testing
- SGLT2i, No SGLT2i
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Chicago
Acute Decompensated Heart Failure
The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure
The main purpose of this study is to observe hemodynamic effects of initiating sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients admitted to the intensive care unit (ICU) with acute decompensated heart failure.
- Trial name
- NCT05346653
- Testing
- SGLT2i, No SGLT2i
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Heart Failure With Preserved Ejection Fraction, End Stage Renal Disease on Dialysis
EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
The presence of CKD has been linked to the development of HFpEF. Currently, the treatment for HFpEF is limited. SGLT2i are one of the few drug classes that have proven efficacy in HFpEF in randomized controlled trials.
- Trial name
- EMPA-PRED (NCT06249945)
- Testing
- Empagliflozin 25 MG
- Where
- 2 sites in Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
Chronic Kidney Diseases, Bone Diseases, Metabolic
Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients
It is a randomized controlled trial in which 100 non diabetic chronic kidney disease (CKD) patient is being participated. Their estimated glomerular filtration rate (eGFR) between 25-75 ml/min/1.73 m2.
- Trial name
- NCT05735197
- Testing
- Dapagliflozin 10mg Tab
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors
Inhibition of dipeptidyl peptidase-4 (DPP-4) or sodium-glucose co-transporter type 2 (SGLT2) has been proposed as a therapeutic target for type 2 diabetes.
- Trial name
- NCT02528019
- Testing
- DPP-4 inhibiotors, SGLT2 inhibitors, Glimepiride
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Kurume University
Diabetic Foot Ulcer
SGLT-i Use in Diabetic Foot Ulcer Disease
Background: People with diabetes and either current or previous diabetic foot ulcer disease (DFUD) are at very high risk for adverse cardiovascular events including heart attacks and strokes.
- Trial name
- NCT06000722
- Testing
- eDelphi method
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Sodium Glucose Co-Transporter 2 Inhibitors, Estimated Glomerular Filtration Rate
Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients
The work aimed to compare the effects of Sodium-glucose co-transporter-2 (SGLT2) inhibitors on glomerular filtration rate (GFR) in patients with diabetic chronic kidney disease (CKD) and non-diabetic CKD.
- Conditions
- Sodium Glucose Co-Transporter 2 Inhibitors, Estimated Glomerular Filtration Rate, Diabetes, Chronic Kidney Disease
- Trial name
- NCT07302464
- Testing
- Sodium Glucose Co-Transporter 2 Inhibitors
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Chronic Kidney Disease, Anemia
SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia
The goal of this clinical trial is to learn if the drug dapagliflozin (an SGLT2 inhibitor) can help protect the kidneys, improve anemia, and support heart health in adults with chronic kidney disease (CKD) who do not have…
- Conditions
- Chronic Kidney Disease, Anemia, Cardiovascular Calcification
- Trial name
- NCT07344922
- Testing
- Dapagliflozin (10Mg Tab) along with standard medical therapy
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Proteinuria, Chronic Kidney Diseases
Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease
We aim to investigate the antiproteinuric effect of adding Dapagliflozin to the standard of care in children with proteinuria.
- Trial name
- NCT04531397
- Testing
- ACEI treatment, Dapagliflozin+ACEI treatment
- Where
- China
- Sponsor
- Children's Hospital of Fudan University
Diabetic Nephropathy Type 2
Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
Diabetes is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease worldwide. Diabetic kidney disease (DKD) is a clinical diagnosis based upon the presence of reduced glomerular filtration rate (GFR)…
- Trial name
- SGLT2i VS ACEi (NCT05373004)
- Testing
- Empagliflozin 25 MG, Enalapril Maleate 20 mg
- Volunteers
- 212 people
- Sponsor
- Omar Tarek Elfarargi
Type 2 Diabetes
SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.
- Trial name
- START (NCT05345327)
- Testing
- Dapagliflozin, Metformin
- Where
- 8 sites in Australia, Sri Lanka
- Volunteers
- 994 people
- Sponsor
- The George Institute
Sodium-glucose Cotransporter 2, Inhibitors
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction
This study aimed to assess the effect of adding sodium glucose co-transporter two inhibitors on clinical outcome and left ventricular function in patients with acute myocardial Infarction.
- Conditions
- Sodium-glucose Cotransporter 2, Inhibitors, Clinical Outcome, Left Ventricule
- Trial name
- NCT06964607
- Testing
- Sodium-glucose cotransporter-2 Inhibitors, Conventional treatment
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Tanta University